Patrys Azione

Patrys Debiti verso fornitori

Il Debiti Commerciali di Patrys (PAB.AX) al 18 ago 2026 è 136.000,00 AUD. L'anno precedente, Debiti Commerciali era 238.400,00 AUD — una variazione del -42,95% (inferiore).

Debiti verso fornitori

136.000,00AUD

YoY

-42,95%

Ultimo aggiornamento:

Debiti Commerciali di Patrys ammonta a 2026 136.000,00 AUD. Debiti Commerciali di Patrys ammontava a 2025 238.400,00 AUD. Diminuisce del -42,95% inferiore rispetto all'anno precedente.
Access this data via the Eulerpool API

Patrys Analisi delle Azioni

Cosa fa Patrys? The company Patrys Ltd is a biotechnology company based in Perth, Australia. It was founded in 2001 by a team of scientists and investors with the aim of developing and marketing targeted cancer treatments. Patrys focuses on the development of monoclonal antibodies and peptides containing therapeutic agents for cancer treatment. The main business model of Patrys is to develop and market new treatment options for cancer patients. The company utilizes the latest advancements in cancer research to develop innovative therapies tailored to the specific characteristics of each type of cancer. Patrys collaborates with leading scientists, research organizations, and pharmaceutical companies to develop a comprehensive portfolio of cancer treatments. Patrys has different business areas, all focused on the development of cancer treatments. One of these areas is the field of monoclonal antibodies, where Patrys concentrates on developing antibodies that can recognize and target specific proteins in cancer tissue. Another area focuses on the development of peptides specifically tailored to cancer cells. Patrys' products cover a variety of cancer types, including lung cancer, breast cancer, prostate cancer, colorectal cancer, and leukemia. The company's leading product is currently the antibody therapeutic PAT-LM1, used for the treatment of lung cancer. PAT-LM1 is a monoclonal antibody that targets a specific protein in the tumor, effectively combating the disease. The drug is currently in phase II clinical trials and showing promising results. Patrys is a company operating in a growing market. The global demand for cancer treatments is increasing, and Patrys has established itself as a significant player in this field. The company has gained recognition in recent years for its innovative therapy approaches and strong research and development team. Patrys aims to provide cancer patients with real hope for a cure and improve their quality of life. Overall, Patrys is a company operating in a rapidly growing market with a promising future. The company has developed a wide range of cancer treatments and works closely with leading experts and pharmaceutical companies to strengthen its position as an innovative and relevant player in cancer research. Patrys has a clear vision that it pursues, presenting an opportunity to play a significant role in the near future in a rapidly growing and highly relevant market. Patrys è una delle aziende più popolari su Eulerpool.com.

Domande frequenti su Patrys azioni

Debiti Commerciali di Patrys è 136.000,00 AUD nel 2026.

Il Debiti Commerciali di Patrys è passato da 238.400,00 AUD a 136.000,00 AUD, con una variazione del -42,95 %. Il valore è inferiore rispetto all'anno precedente.

Su Eulerpool è possibile consultare lo sviluppo storico completo del Patrys di Debiti Commerciali dal 2006, con valori annuali, grafici e analisi dettagliate.

I debiti commerciali rappresentano il denaro dovuto ai fornitori per beni e servizi ricevuti. È un componente fondamentale della gestione del capitale di esercizio.

Il AUD di Debiti Commerciali è un fattore chiave per gli investitori. I cambiamenti in questa metrica possono segnalare il miglioramento o il deterioramento dei fondamentali, impattando direttamente il prezzo delle azioni. Su Eulerpool puoi tracciare il Patrys di Debiti Commerciali storicamente e in tempo reale.

Access this data via the Eulerpool API

Bilancio — Patrys

Tutte le Metriche Finanziarie — Patrys